Alembic
NSE: ALEMBICLTD · Realty
Snapshot
Unlock Alembic's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Alembic Limited is a diversified company primarily engaged in the manufacturing of fermentation and chemistry-based active pharmaceutical ingredients (API) and the development of residential and commercial real estate. The company also generates revenue through project management consultancy, property leasing, and the operation of co-generation and wind power plants.
Business Model
The company operates a hybrid business model, generating income through the production and export of pharmaceutical ingredients alongside the development and leasing of real estate assets. Additional revenue streams are derived from providing consultancy services and selling power generated from its renewable and co-generation energy facilities.
- Co-generation capacity:11 MW
- Wind power capacity:5 MW
Management Commentary
Management focuses on leveraging its historical expertise in pharmaceutical manufacturing while expanding its footprint in the Indian real estate market. The company continues to balance its industrial operations with property development and energy generation activities.
Growth Outlook
Growth is expected to be driven by the continued expansion of its real estate portfolio and the sustained demand for its API products in both domestic and international markets. The company's diversified asset base provides a buffer against sector-specific volatility.
Key Risks
- Regulatory Risk. The pharmaceutical business is subject to stringent quality control and environmental regulations that could impact production costs and market access.
- Real Estate Cyclicality. The company's real estate segment is sensitive to interest rate fluctuations, economic downturns, and changes in urban development policies.
- Operational Concentration. Reliance on specific manufacturing facilities and power plants exposes the company to risks associated with equipment failure or supply chain disruptions.
Start your research today
Unlock AI insights, financials, peers and live data on Alembic and 5,000+ companies — free.
Key Metrics
REVENUE
₹239 Cr
TTM · consolidated
NET PROFIT
₹321 Cr
TTM · consolidated
EPS
₹12.48
TTM · consolidated
RETURN ON EQUITY
13.4%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
6.1%
TTM · consolidated
P/E
8.9x
Q1 FY27 · consolidated
EV/EBITDA
17.8x
Q1 FY27 · consolidated
EBITDA MARGIN
67.7%
TTM · consolidated
NET PROFIT MARGIN
133.1%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Realty
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
AlembicALEMBICLTD | ₹2,861 Cr | 8.93 | 17.75 | 8.2% | 67.7% | 13.4% | 6.1% | +7.0% |
Marathon Nextgen Realty LimitedMARATHON | ₹2,952 Cr | 15.01 | 11.86 | -2.8% | 45.3% | 8.7% | 10.2% | -28.3% |
Elpro International LimitedELPROINTL | ₹2,949 Cr | — | — | — | 30.0% | — | — | +74.7% |
Arvind SmartSpaces LimitedARVSMART | ₹2,947 Cr | 15.75 | 11.07 | 5.3% | 39.4% | 30.3% | 24.2% | +3.0% |
Hubtown LimitedHUBTOWN | ₹2,689 Cr | 28.33 | 11.38 | 28.6% | 53.8% | 4.3% | 9.7% | -43.9% |
OmaxeOMAXE | ₹2,494 Cr | -4.89 | -8.25 | -8.3% | -30.2% | 92.1% | -50.4% | +57.3% |
As of Q1 FY27
Financials
Alembic
NSE: ALEMBICLTD · Realty
Snapshot
Unlock Alembic's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Alembic Limited is a diversified company primarily engaged in the manufacturing of fermentation and chemistry-based active pharmaceutical ingredients (API) and the development of residential and commercial real estate. The company also generates revenue through project management consultancy, property leasing, and the operation of co-generation and wind power plants.
Business Model
The company operates a hybrid business model, generating income through the production and export of pharmaceutical ingredients alongside the development and leasing of real estate assets. Additional revenue streams are derived from providing consultancy services and selling power generated from its renewable and co-generation energy facilities.
- Co-generation capacity:11 MW
- Wind power capacity:5 MW
Management Commentary
Management focuses on leveraging its historical expertise in pharmaceutical manufacturing while expanding its footprint in the Indian real estate market. The company continues to balance its industrial operations with property development and energy generation activities.
Growth Outlook
Growth is expected to be driven by the continued expansion of its real estate portfolio and the sustained demand for its API products in both domestic and international markets. The company's diversified asset base provides a buffer against sector-specific volatility.
Key Risks
- Regulatory Risk. The pharmaceutical business is subject to stringent quality control and environmental regulations that could impact production costs and market access.
- Real Estate Cyclicality. The company's real estate segment is sensitive to interest rate fluctuations, economic downturns, and changes in urban development policies.
- Operational Concentration. Reliance on specific manufacturing facilities and power plants exposes the company to risks associated with equipment failure or supply chain disruptions.
Start your research today
Unlock AI insights, financials, peers and live data on Alembic and 5,000+ companies — free.
Key Metrics
REVENUE
₹239 Cr
TTM · consolidated
NET PROFIT
₹321 Cr
TTM · consolidated
EPS
₹12.48
TTM · consolidated
RETURN ON EQUITY
13.4%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
6.1%
TTM · consolidated
P/E
8.9x
Q1 FY27 · consolidated
EV/EBITDA
17.8x
Q1 FY27 · consolidated
EBITDA MARGIN
67.7%
TTM · consolidated
NET PROFIT MARGIN
133.1%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.0x
Q1 FY27 · consolidated
Peers · Realty
As of Q1 FY27